Please use this identifier to cite or link to this item: http://hdl.handle.net/10397/108427
PIRA download icon_1.1View/Download Full Text
DC FieldValueLanguage
dc.contributorDepartment of Applied Biology and Chemical Technology-
dc.creatorTan, H-
dc.creatorGong, Y-
dc.creatorLiu, Y-
dc.creatorLong, J-
dc.creatorLuo, Q-
dc.creatorFaleti, OD-
dc.creatorLyu, X-
dc.date.accessioned2024-08-19T01:58:20Z-
dc.date.available2024-08-19T01:58:20Z-
dc.identifier.issn0753-3322-
dc.identifier.urihttp://hdl.handle.net/10397/108427-
dc.language.isoenen_US
dc.publisherElsevier Massonen_US
dc.rights© 2023 The Authors. Published by Elsevier Masson SAS. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).en_US
dc.rightsThe following publication Tan, H., Gong, Y., Liu, Y., Long, J., Luo, Q., Faleti, O. D., & Lyu, X. (2023). Advancing therapeutic strategies for Epstein-Barr virus-associated malignancies through lytic reactivation. Biomedicine & Pharmacotherapy, 164, 114916 is available at https://doi.org/10.1016/j.biopha.2023.114916.en_US
dc.subjectCarcinogenesisen_US
dc.subjectEBVen_US
dc.subjectLytic reactivationen_US
dc.subjectTherapiesen_US
dc.titleAdvancing therapeutic strategies for Epstein-Barr virus-associated malignancies through lytic reactivationen_US
dc.typeJournal/Magazine Articleen_US
dc.identifier.volume164-
dc.identifier.doi10.1016/j.biopha.2023.114916-
dcterms.abstractEpstein-Barr virus (EBV) is a widespread human herpes virus associated with lymphomas and epithelial cell cancers. It establishes two separate infection phases, latent and lytic, in the host. Upon infection of a new host cell, the virus activates several pathways, to induce the expression of lytic EBV antigens and the production of infectious virus particles. Although the carcinogenic role of latent EBV infection has been established, recent research suggests that lytic reactivation also plays a significant role in carcinogenesis. In this review, we summarize the mechanism of EBV reactivation and recent findings about the role of viral lytic antigens in tumor formation. In addition, we discuss the treatment of EBV-associated tumors with lytic activators and the targets that may be therapeutically effective in the future.-
dcterms.accessRightsopen accessen_US
dcterms.bibliographicCitationBiomedicine and pharmacotherapy, Aug. 2023, v. 164, 114916-
dcterms.isPartOfBiomedicine and pharmacotherapy-
dcterms.issued2023-08-
dc.identifier.scopus2-s2.0-85162239160-
dc.identifier.pmid37229802-
dc.identifier.eissn1950-6007-
dc.identifier.artn114916-
dc.description.validate202408 bcch-
dc.description.oaVersion of Recorden_US
dc.identifier.FolderNumberOA_Scopus/WOSen_US
dc.description.fundingSourceOthersen_US
dc.description.fundingTextNational Natural Science Foundation of China, China; Guangdong Basic and Applied Third Basic Research Foundation, China; President Foundation of the Affiliated Hospital, Southern Medical Universityen_US
dc.description.pubStatusPublisheden_US
dc.description.oaCategoryCCen_US
Appears in Collections:Journal/Magazine Article
Files in This Item:
File Description SizeFormat 
1-s2.0-S0753332223007060-main.pdf2.15 MBAdobe PDFView/Open
Open Access Information
Status open access
File Version Version of Record
Access
View full-text via PolyU eLinks SFX Query
Show simple item record

Page views

35
Citations as of Apr 14, 2025

Downloads

10
Citations as of Apr 14, 2025

SCOPUSTM   
Citations

12
Citations as of Dec 19, 2025

WEB OF SCIENCETM
Citations

12
Citations as of Dec 18, 2025

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.